MULTIPLE SCLEROSIS

Category: Pathology

News

  • IMPROVE study results released

    MERCK has release the results of its completed 40-week IMPROVE (Investigating MRI Parameters with Rebif improved formulation) study.

    14/09/2009

  • Merck releases CLARITY trial data

    MERCK has announced new data from a post-hoc analysis of the two-year placebo-controlled CLARITY1 Phase III trial using a short-course of Cladribine Tablets to treat patients with relapsing-remitting multiple sclerosis (MS).

    14/09/2009

  • Merck release Phase III Clarity1 trial for MS

    Merck release Phase III Clarity1 trial for MS

    MERCK has announced the results from its 96-week placebo controlled Clarity1 Phase III trial using oral Cladribine Tablets to treat patients with relapsing-remitting multiple sclerosis (MS).

    30/04/2009

  • Rebranded MS treatment available

    Rebranded MS treatment available

    NOVARTIS has launched Extavia, a rebranded version of the standard-of-care treatment for relapsing forms of multiple sclerosis (MS).

    28/01/2009

  • FDA approval of MS therapy Extavia

    NOVARTIS has announced the FDA approval of Extavia, the first in the company’s portfolio of planned multiple sclerosis (MS) therapies to help patients suffering the disease.

    24/08/2009

  • Merck expands R&D in China

    Merck intends to expand its research and development (R&D) presence in China by making it the company's fourth key R&D hub for Merck Serono division worldwide. Merck plans to invest more than 150 million Euros.

    24/11/2009

 

Products

  • Bayer launches titrations pack for MS

    Bayer launches titrations pack for MS

    BAYER has announced the launch of its titration pack developed to help patients with Multiple Sclerosis (MS) start Betaferon (interferon beta-1b) therapy.

 

Find more information about multiple sclerosis on our other sites.

to get Clinical Lab
delivered to your inbox

Latest from Twitter

    Getting your tweets...